A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Clinical trial NCT07081646 · RECRUITING

Trial details

NCT number: NCT07081646
Sponsor: Alexion Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed AL Amyloidosis Refractory AL Amyloidosis Light Chain Amyloidosis Amyloidosis

Start date: 2025-08-18
Primary completion: 2029-08-15
Enrollment: 91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.